Anti-diabetic Effects of Extract of *Momordica charantia* (Karela) Fruits and Camel Milk Compared to Dibenol on Induced Diabetic Rats

Kandil Abdel-Hai Ali Attia**, Halima Yahya Sharahili, Shaima Abd Al-ellah Al Harbi, Laila Mohammad Mutaen, Maraym Ali Somaly and Eman Abdu Qahar

*Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Saudi Arabia*  
**Current address: Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Saudi Arabia. Postal code: 82621/P.O. Box: 2349  
*Permanent address: Evaluation of Natural Resources Department, Environmental Studies and Research Institute, University of El-Sadat City, El-Sadat City, Sixth Zone, Egypt*

**Corresponding author.**

**A b s t r a c t**

This study aimed to evaluate the anti-diabetic effects of aqueous extract of karela fruits and camel milk compared to dibenol on the streptozotocin (STZ) induced diabetic rats by assaying liver and kidney functions. Forty-two male albino rats were divided into 7 equal groups. Group I were given normal feed and water, groups II and III received orally (75 ml/rat/day) camel milk and extract of karela (800 mg/kg) respectively. Intraperitoneal injection of STZ (60 mg/kg) was used for inducing diabetes mellitus in groups IV, V, VI and VII. Groups V, VI and VII treated orally with dibenol (5mg/kg), camel milk and extract of karela respectively for 30 days. Blood glucose levels for each rat were determined before STZ dosing and after 3, 10, 30 days of administration. Blood samples were collected at the end of the experiment for estimation blood glucose concentration as well as kidney and liver functions parameters. The glucose level was decreased in rats treated with aqueous extract of karela or camel milk. Moreover, the ALT, AST, ALP enzymes, urea, creatinine and uric acid were decreased. It could be concluded that either karela or camel milk have anti-hyperglycemic effects and may be used to manage diabetes mellitus.

**A r t i c l e  I n f o**

Accepted: 11 October 2016  
Available Online: 06 November 2016

**K e y w o r d s**

Camel milk  
Diabetes  
Dibenol  
Induced diabetic rats  
Karela

**I n t r o d u c t i o n**

Diabetes mellitus (DM) is considered as one of the five leading causes of death in the world (Joseph and Jini, 2011). DM is the 3rd cause of death in Saudi Arabia (World Health Ranking, 2010). The global estimated that the prevalence of diabetes from 171 million in 2000 to 366 million in 2030 (Shaw et al., 2010). The number of people who suffer from DM increased from 890,000 in 2000 to a staggering projection of 2,523,000 in 2030 in Saudi Arabia (Al-Baghli et al., 2010). In 2011, Saudi Arabia reported a prevalence of DM at 30% of the total population, with a rate of 27.6% in women and 34.1% in men (El-Bab et al., 2012).

DM is a group of diseases marked by high levels of blood glucose resulting from defects in insulin production from the pancreatic β-cells (Jarald et al., 2008), insulin action, or both. Diabetes is associated with the generation of reactive oxygen species which cause oxidative damage particularly
to heart, kidney, eyes, nerves and liver (Orsolic and Basic, 2008; Obrosova et al., 2003). The disease causes morbidity and long-term complications, including cardiomyopathy, angiopathy, neuropathy, retinopathy, nephropathy, diabetic food and digestive insufficiencies (Karunanayake and Tennekoon, 1993; Yeh et al., 2003). There are different groups of oral hypoglycemic drugs and insulin for clinical use, having adverse side effects, including hematological, cutaneous and gastrointestinal reactions, hypoglycemic coma and disturbances of liver and kidney functions (Holman and Turner, 1991; Williams and Pickup, 1991; Kameswara Rao et al., 1997). Dibenol (glybincalmine) is one of an orally effective hypoglycaemic drug that reduces blood sugar concentration. It stimulates the mobilization of endogenous insulin. Management of diabetes without any side effects is still a challenge to the medical system. This leads to increasing the demand for complementary and alternative medicine with antidiabetic activity and fewer side effects. Several studies showed that Momordica charantia has anti-diabetic, anti-viral, anti-tumour, anti-oxidant, anti-inflammatory and hypo-cholestrolemic, hypoglycemic and immune-stimulant properties (Biswas et al., 1991; Ahmed et al., 1999; Naseem et al., 1998). Camel’s milk (CM) is an excellent source of well-balanced nutrients and exhibits a range of biological activities. CM used therapeutically against Dropsy, jaundice, problems of the spleen, tuberculosis, asthma, anemia, piles and diabetes. It also has antibacterial and antiviral activities (Agrawal et al., 2005; Redwan and Tabll, 2007). Therefore, the aim of the present study was to evaluate the anti-diabetic effects of extract of karela fruits and camel milk compared to dibenol (synthetic medicine) on blood glucose level, liver and kidney functions on the streptozotocin induced diabetic rats.

**Materials and methods**

This investigation was carried out in the labs of Medical Laboratory Technology Department, College of Applied Medical Sciences, and Medical Research Center, Jazan University.

**Preparation of the aqueous extract of M. charantia fruits**

The fruits of *M. charantia* were collected from local market in Jazan city. To obtain karela fruits aqueous extract, this unripe fresh karela fruits were carefully and thoroughly washed in tap water. The fruits were sliced into two halves and the seeds were removed manually, then the fleshy parts were cut into small pieces. Then 1 kg seedless flesh was put into an electric juicer to make juice and it is then filtered through a piece of clean silk cloth. The filtered juice was evaporated to slurry in vacuum rotatory evaporator and temperature was maintained around 45°C, and the concentrated slurry mass was completely lyophilized by continuous freeze drying operation for 72 hrs and kept at -20°C in refrigerator in air tight container until use.

**Chemicals and kits**

Streptozotocin, glibenclamide and diagnostic kits for liver and kidney functions such as ALT, AST, ALP, urea, uric acid, and creatinine were purchased from the Sigma-Aldrich Co.

**Camel milk**

The milk was collected from female lactating healthy domestic camels (*Camelus dromedaries*). The samples were collected from desert living animals in Jazan region, Kingdom of Saudi Arabia, then after were transported in icebox in two hours to lab.

**Maintenance of animals and approval of protocol**

Forty-two healthy male albino rats of Wistar strain, weighing 220–280 g, were used for the present investigation. They were housed in clean cages and maintained in an air-conditioned experimental room at 12-hr light: dark cycles. The animals were acclimatized to laboratory condition for one week prior to experiment. Standard pellets were used as a basal diet during the experimental period. The control and experimental animals were provided with purified drinking water *ad libitum*. The animals were maintained in accordance with according to the European Communities Council Directive of 1986 (EC 86/609) and approved by the Ethical Committee for Animal Experimentation at Medical Research Center, Jazan University. Before starting the experiment, the animals were carefully marked on different parts of their body, which was later used as identification mark for a particular animal, so that the response of a particular mouse prior to and after the administration could be noted separately.

**Induction of diabetes in experimental animals**

Diabetes mellitus was induced in overnight fasted rats by a single intraperitoneal injection of streptozotocin at the rate of 60 mg/kg body weight dissolved in 10 mM sodium citrate buffer (pH 4.5), while the control group was given only normal feed and water (Saeed et al.,
2008). The animals were allowed free access to 5% glucose solution to overcome the drug induced hypoglycaemia. Blood glucose level of these rats was estimated 72 hr after streptozotocin administration, and diabetes was confirmed by blood samples collected from the tip of the tail using a blood glucometer. Animals with blood glucose level equal to or more than 200mg/dL were declared diabetic and were used in entire experimental groups (Lenzen, 2008).

Experimental designs

Seven groups of rats, six rats in each, received the following treatment schedule:

- **Group I:** Normal control rats were given only normal feed and water.
- **Group II:** Rats received camel milk (75 mL/rat/day) for 30 days.
- **Group III:** Received aqueous extract of *M. charantia* fruit (800mg/kg dissolved in 10 ml distilled water) by stomach tube.
- **Group IV:** Rats subjected to intraperitoneal injection (i.p.) of STZ (60 mg/kg) used for inducing diabetes mellitus.
- **Group V:** Rats of STZ induced DM were treated with dibenol (glibenclamide 5 mg/kg, suspended in 10 ml distilled water) up to day 30.
- **Group VI:** Rats of STZ induced DM were orally received camel milk 75 ml/rat/day for 30 days.
- **Group VII:** Rats of STZ induced DM were orally received aqueous extract of *M. charantia* fruit (800mg/kg dissolved in 10 ml distilled water) for 30 days.

Collection of blood samples and estimation of serum biochemical investigations

After the last dose, animals were fasted for 12 hours and the rats were anesthetized by diethyl ether. Blood was drawn via heart puncture into tubes. Serum was separated from the clot by centrifuging at 3000 rpm for 15 min at room temperature. Serum was collected carefully and kept at −20°C until analysis of fasting blood glucose concentration was determined by commercially available glucose kit based on Trinder (1969). Spectrophotometric diagnostic kits were used for estimation kidney and liver function tests including determination of ALT, AST and ALP activities (Moss, 1982; Young, 1990), urea (Fawcett and Scott, 1960), uric acid (Fossati et al., 1980), and creatinine levels (Stein, 1986) in serum.

**Body weight**

The body weight of rat of each group was measured just before and 10; 30 days after induction of diabetes and administration of karela, camel milk and dibenol.

**Statistical analysis**

Data from the experiments were presented as mean ± standard deviation. Statistical analysis was done by using the SPSS for Windows. The level of significance was set at $p<0.01$.

**Results and discussion**

Diabetes mellitus is a serious disease with multiple complications that is rising dramatically worldwide. STZ is the drug that selectively destroys β cells, insulin producing pancreatic endocrine cells, and thus induces experimental diabetes mellitus (Brenna et al., 2003).

The present study showed that daily treatment for 30 days with raw camel (75 ml/rat) has anti-hyperglycemic effect for the STZ-diabetic rats where mean blood glucose level reduced significantly from 383 ± 70.4 to 264± 30.3 (Table 1). These results are in agreement with Khan et al. (2013) who reported that the blood glucose levels of diabetic rats that were fed fresh camel milk reduced significantly from 560 mg/dL to 235 mg/dL after 30 days. Also, Badr (2013) found that STZ-induced diabetic mice treated with camel milk whey protein displayed a significant reduction in blood glucose levels from 411 ± 37 mg/dL to 261 ± 25.5 mg/dL after 2 weeks. Similar results were reported by Agrawal et al. (2005) in rats; Agrawal et al. (2011) in human; El-Said et al. (2010) in rabbits and Sboui et al. (2010) in dogs. This reduction may be related to the presence of 52 micro unit/ml of insulin-like protein in camel milk which mimic insulin interaction with its receptor. Moreover, the higher content of zinc in camel milk (Mehaia et al., 1995) has a key role in insulin secretory activity in pancreatic beta cells. Beg et al. (1986) found that the amino acid sequence of some camel milk protein is rich in cysteine/half-cystine, which has a superficial similarity with the insulin family peptides. In addition, camel milk possesses a different casein content, a high amount of both polyunsaturated fatty acids (C18:1-C18:3) and vitamin B3 and large lipid micelles (Farah, 1993 and Al-Humaid et al., 2010). Furthermore, the small size and weight of camel milk immunoglobulin may offer enormous potential through interaction with the host cell protein and cause an induction of regulatory
cells and finally result in a downward regulation of the immune system and β-cell salvage (Agrawal et al., 2007a, b).

The current study indicated that aqueous extract of *M. charantia* for a period of 30 days (800 mg/kg) produced a significant reduction in the blood glucose levels of the STZ-diabetic rats from 337.5 ± 32.8 to 272.3 ± 15.7 (Table 1). These results are consistent with data reported by Hossain et al. (2014) who found that administration of aqueous extract of *M. charantia* fruits by 750 mg/kg in rats was able to reduce blood glucose level significantly compared with the diabetic control group. Also Ragasa et al. (2011) and Sarandan et al. (2010) confirmed that various extracts and compounds of *M. charantia* have antidiabetic properties. In other studies, on rabbits *M. charantia* extract had a hypoglycemic effect (Akhtar et al., 2011). They attributed this effect to the saponin and glycosidic components present in the plant. A number of reported clinical studies have shown that *M. charantia* extract from the fruits, seeds and leaves contains several bioactive compounds that have hypoglycemic activity in both diabetic animals and human (Wehash et al., 2012; Fuanchan et al., 2011). These bioactive components may work as ligands for peroxisome proliferator activated receptors, ligand-activated transcription factors important in modulating both lipid and glucose metabolism (Chuang et al., 2006; Chao and Huang, 2003).

The hypoglycemic effect of *M. charantia* may be attributed to its content of a peptide resembling insulin (charantin) (Parkash et al., 2002). The decrease in the blood glucose level in the present treated animals could be related either to the partial regeneration or the preservation of the pancreatic β cell mass by *M. charantia* in rats (Hossain et al., 2014; Ahmed et al., 1999). Finally, another potential hypoglycemic mechanism of action of *M. charantia* is by decreasing Na+ and K+-dependent glucose absorption at the brush border membrane (Meir and Yaniv, 1985; Singh et al., 2004) and inhibiting intestinal monosaccharide and amino acid uptake (Mahomoodally et al., 2004). Moreover, *M. charantia* has been shown to modulate activities of intestinal and renal disaccharidases in STZ-induced diabetic rats (Shetty et al., 2005). The results declared that the ameliorative effect by camel milk was higher than either karela or dibenol on blood glucose levels as shown in Table 1.

### Table 1. Influence of karela, camel milk and dibenol administration on blood glucose levels mg/dL (mean ± STD) of diabetic rats comparing to control untreated groups.

<table>
<thead>
<tr>
<th>Group no.</th>
<th>Baseline</th>
<th>After 10 days</th>
<th>After 30 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>116.2±8.2</td>
<td>123.8±8.9</td>
<td>120.3±11.5</td>
</tr>
<tr>
<td>Group II</td>
<td>104.3±6.9</td>
<td>115.4±13.02</td>
<td>118.3±3.5</td>
</tr>
<tr>
<td>Group III</td>
<td>127.8±15.2</td>
<td>105.2±9.2</td>
<td>105.8±7.6</td>
</tr>
<tr>
<td>Group IV</td>
<td>360.4±26.6</td>
<td>377.6±16.1</td>
<td>376.6±8.9</td>
</tr>
<tr>
<td>Group V</td>
<td>359.5±14.7</td>
<td>341.6±26.2</td>
<td>290.3±8.5</td>
</tr>
<tr>
<td>Group VI</td>
<td>383.6±70.4</td>
<td>300.5±29.6</td>
<td>264±30.3</td>
</tr>
<tr>
<td>Group VII</td>
<td>337.5±32.8</td>
<td>306.7±17.7</td>
<td>282.8±42.3</td>
</tr>
</tbody>
</table>

Values are means of 6 rats ± STD. Means with different superscripts in the same column are significantly different (p<0.01).

### Table 2. Effects of karela, camel milk and dibenol on body weight (gm.) (mean ± STD) in diabetic rats comparing to control untreated groups.

<table>
<thead>
<tr>
<th>Group no.</th>
<th>Baseline</th>
<th>After 10 days</th>
<th>After 30 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>269.5±19</td>
<td>283.2±27.4</td>
<td>284.7±26</td>
</tr>
<tr>
<td>Group II</td>
<td>260.5±18.2</td>
<td>275.2±21.2</td>
<td>280.2±9.3</td>
</tr>
<tr>
<td>Group III</td>
<td>241.±11.2</td>
<td>258.2±4.9</td>
<td>244.3±18.7</td>
</tr>
<tr>
<td>Group IV</td>
<td>259.5±18.7</td>
<td>223.2±19.9</td>
<td>195.7±14.6</td>
</tr>
<tr>
<td>Group V</td>
<td>271.8±15.2</td>
<td>210.2±7.8</td>
<td>196.8±7.2</td>
</tr>
<tr>
<td>Group VI</td>
<td>256.5±5.1</td>
<td>185.2±9.6</td>
<td>177±10.7</td>
</tr>
<tr>
<td>Group VII</td>
<td>229.6±5.1</td>
<td>202.3±10.8</td>
<td>197.2±7.7</td>
</tr>
</tbody>
</table>

Values are means of 6 rats ± STD. Means with different superscripts in the same column are significantly different (p<0.01).

The present data revealed that the body weight after 30 days of treatment in untreated control groups (Groups I, II and III) were significantly increased than at the beginning of the experiment, on the contrary a significant decrease body weight was observed in diabetic treated group (Group IV) (p<0.01) (Table 2). On the other hand, the administration of camel milk or aqueous extracts of *M. charantia* to the diabetic animals (Groups VI and VII respectively) showed slightly improvement in the body weight. These changes in body weights in all groups of

---

K. A. A. Attia et al. (2016) / Anti-diabetic Effects of Extract of *Momordica charantia* (Karela) Fruits and Camel Milk Compared to Dibenol on Induced Diabetic Rats
animals were given in Table 1. These results are in agreement with Ahn et al. (2006) who showed that the body weight was significantly decreased in STZ-diabetic rats. The ability of *M. charantia* or camel milk to protect body weight loss seems to be due to their ability to reduce hepato-renal dysfunction. They might enhance glucose utilization and improve diabetes associated disorders because it significantly decreased the blood glucose level as in Table 1.

Elevation in the liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in diabetic patients reflect the concentration of intracellular hepatic enzymes that have leaked into the circulation and serve as a marker of hepatocyte injury (Harris, 2005). The current study indicated that ALT, AST, ALP, urea, creatinine and uric acid were significantly elevated in STZ–DM rats as compared to control groups (Groups I, II and III) as shown in Tables 3 and 4. While administration either camel milk or aqueous extracts of *M. charantia* (Groups VI and VII respectively) to the induced diabetic rats showed that ameliorative effects of liver and kidney functions parameters as compared to positive diabetic control group (Group IV) (Table 3). These results are in agreement with Hamad et al. (2011), Khan et al. (2013), and, Korish and Arafah (2013). The beneficial health effects of camel milk to the liver and kidney function could be attributed to its antioxidant activity (Al-Humaid et al., 2010). It has been reported that camel milk contains high levels of vitamins (A, B2, C and E) and is rich in magnesium (Knoess, 1979). These vitamins are antioxidants that have been found useful in preventing tissue injury caused by toxic agents like STZ (Yakaryilmaz et al., 2007). Additionally, camel milk is rich in Zinc (Knoess, 1979), a trace element essential for living organisms. More than 300 enzymes require Zn for their activity and it has a relationship with many enzymes in the body and can prevent cell damage through activation of antioxidant system (Powell, 2000; Ozturk et al., 2003; Ozdemir and Inane, 2005).

The bioactive components of aqueous extracts of *M. charantia* may be responsible for many of the proposed health benefits such as charantin, glycosides such as mormordin, antioxidants such as vitamin C, carotenoids, flavanoids, and polyphenols and polypeptide p or plant insulin (Khanha et al., 1981; Lotlikar and Rajarama Rao, 1966; Jantan et al., 2005; Anila and Vijayalakshmi, 2000). The present study showed that the administration of karela in Group VII significantly reduced AST and ALP activity followed by dibenol (Group V) and camel milk (Group VI) respectively as shown in Table 3. While dibenol was higher effective than either karela or camel milk on reduction of activity of ALT enzyme. Moreover, administration of karela was more effective on reduction of serum creatinine and urea than either camel milk or dibenol. On the contrary, the dibenol has a significant effect on reduction of serum uric acid followed by camel milk and karela respectively (Table 4).

### Table 3. Influence of karela, camel milk and dibenol administration on liver functions (IU/L) (mean ± STD).

<table>
<thead>
<tr>
<th>Group no.</th>
<th>AST (IU/L)</th>
<th>ALT (IU/L)</th>
<th>ALP (IU/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>176.5^a± 52.9</td>
<td>89.3^a±12.7</td>
<td>361.1^a±56.7</td>
</tr>
<tr>
<td>Group II</td>
<td>165.6^a± 44.7</td>
<td>71.7^a±14.9</td>
<td>351.4^a±42.8</td>
</tr>
<tr>
<td>Group III</td>
<td>158.3± 22.2</td>
<td>70.7^a± 7.8</td>
<td>274.3±67.1</td>
</tr>
<tr>
<td>Group IV</td>
<td>215.7^b±59.9</td>
<td>143.8^b±43.4</td>
<td>635.5±69.7</td>
</tr>
<tr>
<td>Group V</td>
<td>152.3^b±49.9</td>
<td>111.8^b±17.6</td>
<td>255.7^b±55.1</td>
</tr>
<tr>
<td>Group VI</td>
<td>184.5^b±5.9</td>
<td>134.9^b±18.7</td>
<td>372.9^b±39.9</td>
</tr>
<tr>
<td>Group VII</td>
<td>135.7±44.7</td>
<td>131^b±41.9</td>
<td>282.8^b±42.3</td>
</tr>
</tbody>
</table>

Values are means of 6 rats ± STD. Means with different superscripts in the same column are significantly different (*p*< 0.01).

### Table 4. Influence of karela, camel milk and dibenol administration on kidney functions (mean ± STD).

<table>
<thead>
<tr>
<th>Group no.</th>
<th>Urea (mmol/L)</th>
<th>Creatinine (µmol/L)</th>
<th>Uric acid (µmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>7.5±0.9</td>
<td>29.8±6.8</td>
<td>113.7±12.7</td>
</tr>
<tr>
<td>Group II</td>
<td>6.9±1.2</td>
<td>28±3.6</td>
<td>92^b±10.4</td>
</tr>
<tr>
<td>Group III</td>
<td>6.9±0.4</td>
<td>27.7±6.2</td>
<td>96.7±10.3</td>
</tr>
<tr>
<td>Group IV</td>
<td>13.1^b±0.6</td>
<td>38±4.5</td>
<td>65.7±5.7</td>
</tr>
<tr>
<td>Group V</td>
<td>9.3±2.6</td>
<td>28±7.6</td>
<td>32.7±12.3</td>
</tr>
<tr>
<td>Group VI</td>
<td>8.6±2.1</td>
<td>29±2.3</td>
<td>55.4±5.3</td>
</tr>
<tr>
<td>Group VII</td>
<td>8.9±1.4</td>
<td>25.3±5.1</td>
<td>57.3±25.6</td>
</tr>
</tbody>
</table>

Values are means of 6 rats ± STD. Means with different superscripts in the same column are significantly different (*p*< 0.01).
Conclusion

It could be concluded that, camel milk or aqueous extracts of *M. charantia* has a powerful effect in reducing blood glucose levels and they limit diabetic complications such as elevated markers enzymes and parameters of liver and kidney diseases in rats. Camel milk and *M. charantia* has a significant role in treatment of diabetes may due to its content of insulin/insulin-like proteins. So camel milk and karela fruits are important for human especially diabetic patients. Further studies are needed to isolate the actual bioactive peptides, in camel milk and karela fruits, which responsible for reducing blood glucose, markers enzymes and parameters of liver and kidney in diabetic patients.

Conflict of interest statement

Authors declare that they have no conflict of interest.

Acknowledgement

We are keenly grateful to Scientific Research Deanship, Jazan University for supporting this work by grant number FS3-035. Also we are thankful to Medical Research Center for providing us with the animal models. Finally, we are very grateful to the supervisor of animal house of Medical Research Center Dr. Emad ElSayed Shahin, for assisting during practical part in animal house.

References


Saeed, M. K., Deng, Y., Dai, R., 2008. Attenuation of
How to cite this article: 